Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

A retrospective analysis of PTCY vs ATG performed form ALWP of EBMT and contribution of our team. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka,Dr Vadratsikas

Our institutional guidelines discussed Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

The first successful trial in steroid refractory GVHD. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

We discussed a case of CNS lymphoma and the diffrent HD regimens. we favour regimens with Rituxmab, Thiotepa and bu or AraC   R-Busulfan-thiotepa Rituximab -6 Busulfan 2 days -5, -4 Thiotepa 5 mg/kg days -4 and -3   (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5473-z)   Other regimens Regimen without Thiotepa BUCYE Busulfan 3.2 mg/kg days...

We discussed the current EBMT guidelines for COVID19. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

The current Indications for HCT were discussed. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

This cohort analysis evaluates theincidence, risk factors and mortality of pre-engraftment blood-stream infections(BSIs) and ds-DNAviral infections (VIs) after HSCTwith post-transplant cyclophosphamide(PT-Cy) platform among different donor sourcesAllogeneic HSCT with PT-Cy showed a 32% incidence of pre-engraftment BSIsand donor type did not affect their occurrence·VIsare common in early...